The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ

Oncogene

Volumn 33, Issue 23, 2014, Pages 3033-3042

  Ory, V ^a   Tassi, E ^a   Cavalli, L R ^a   Sharif, G M ^a   Saenz, F ^a   Baker, T ^a   Schmidt, M O ^a   Mueller, S C ^a   Furth, P A ^a   Wellstein, A ^a   Riegel, A T ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

AIB1; coactivator; DCIS; tumor initiating cells; xenografts

Indexed keywords

GAMMA UROGASTRONE; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR HES 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; TUMOR GROWTH; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; NUCLEAR RECEPTOR COACTIVATOR 3; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902140877     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.263     Document Type: Article

References (44)

1. Radford DM, Phillips NJ, Fair KL, Ritter JH, Holt M, Donis-Keller H. Allelic loss and the progression of breast cancer. Cancer Res 1995; 55: 5180-5183.
2. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995; 175: 195-201.
3. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004; 36: 984-988. (Pubitemid 39167495)
4. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 5974-5979. (Pubitemid 36576916)
5. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003; 1: 362-375. (Pubitemid 36437922)
6. Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ? Nat Rev 2011; 11: 68-75.
7. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-968. (Pubitemid 27366683)
8. York B, OMalley BW. Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem 2010; 285: 38743-38750.
9. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. The role and regulation of the nuclear receptor co-Activator AIB1 in breast cancer. Breast Cancer Res Treat 2009; 116: 225-237.
10. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004; 6: 263-274. (Pubitemid 39222039)
11. Kuang SQ, Liao L, Wang S, Medina D, OMalley BW, Xu J. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen- induced mammary tumorigenesis. Cancer Res 2005; 65: 7993-8002. (Pubitemid 41297279)
12. Fereshteh MP, Tilli MT, Kim SE, Xu J, OMalley BW, Wellstein A et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 2008; 68: 3697-3706.
13. Nakles RE, Shiffert MT, Daz-Cruz ES, Cabrera MC, Alotaiby M, Miermont AM et al. Altered AIB1 or AIB1D3 expression impacts ERa effects on mammary gland stromal and epithelial content. Mol Endocrinol 2011; 25: 549-563.
14. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000; 92: 1185-1186.
15. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13: 394-406. (Pubitemid 351609443)
16. Chien CD, Kirilyuk A, Li JV, Zhang W, Lahusen T, Schmidt MO et al. Role of the nuclear receptor coactivator AIB1-{Delta}4 in the control of gene transcription J Biol Chem 2011; 286: 26813-26827.
17. Qutob MS, Bhattacharjee RN, Pollari E, Yee SP, Torchia J. Microtubule-dependent subcellular redistribution of the transcriptional coactivator p/CIP. Mol Cell Biol 2002; 22: 6611-6626. (Pubitemid 34946992)
18. Long W, Yi P, Amazit L, LaMarca HL, Ashcroft F, Kumar R et al. SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell 2010; 37: 321-332.
19. Miller FR. Xenograft models of premalignant breast disease. J Mammary Gland Biol Neopl 2000; 5: 379-391. (Pubitemid 32236769)
20. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002; 111: 29-40.
21. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001; 3: 785-792. (Pubitemid 32842683)
22. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
23. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007; 21: 299-310. (Pubitemid 47529469)
24. Stingl J, Raouf A, Emerman JT, Eaves CJ. Epithelial progenitors in the normal human mammary gland. J Mamm Gland Biol Neopl 2005; 10: 49-59. (Pubitemid 40724022)
25. Xu J, Wu RC, OMalley BW. Normal and cancer-related functions of the p160 steroid receptor co-Activator (SRC) family. Nat Rev 2009; 9: 615-630.
26. Cody HS. Sentinel lymph node biopsy for DCIS: are we approaching consensus? Ann Surg Oncol 2007; 14: 2179-2181.
27. Sung YM, Xu X, Sun J, Mueller D, Sentissi K, Johnson P et al. Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One 2009; 4: e7445.
28. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 2008; 3: 429-441.
29. Korkaya H, Wicha MS. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 2009; 15: 1845-1847.
30. Pradeep CR, Kostler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J et al. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 2012; 31: 907-917.
31. Nofech-Mozes S, Spayne J, Rakovitch E, Hanna W. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol 2005; 12: 256-264. (Pubitemid 41463806)
32. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/ progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-6130.
33. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C et al. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci USA 2012; 109: 221-226.
34. Lauritsen KJ, List HJ, Reiter R, Wellstein A, Riegel AT. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 2002; 21: 7147-7155. (Pubitemid 35305601)
35. Torres-Arzayus MI, Zhao J, Bronson R, Brown M. Estrogen-dependent and estrogen- independent mechanisms contribute to AIB1-mediated tumor formation. Cancer Res 2010; 70: 4102-4111.
36. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF- 10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268. (Pubitemid 36677560)
37. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4: 359-365. (Pubitemid 46766981)
38. Oh A, List H-J, Reiter R, Mani A, Zhang Y, Gehan E et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 2004; 64: 8299-8308. (Pubitemid 39491768)
39. Cavalli LR, Man YG, Schwartz AM, Rone JD, Zhang Y, Urban CA et al. Amplification of the BP1 homeobox gene in breast cancer. Cancer Genet Cytogenet 2008; 187: 19-24.
40. Cavalli LR, Santos SC, Broustas CG, Rone JD, Kasid UN, Haddad BR. Assignment of the BLID gene to 11q24.1 by fluorescence in situ hybridization. Cancer Genet Cytogenet 2008; 186: 120-121.
41. Al-Otaiby M, Tassi E, Schmidt MO, Chien CD, Baker T, Salas AG et al. Role of the nuclear receptor coactivator AIB1/SRC-3 in angiogenesis and wound healing. Am J Pathol 2012; 180: 1474-1484.
42. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283-1298.
43. Rosenfield SM, Bowden ET, Cohen-Missner S, Gibby KA, Ory V, Henke RT et al. Pleiotrophin (PTN) expression and function and in the mouse mammary gland and mammary epithelial cells. PLoS One 2012; 7: e47876.
44. Schmittgen TD, Livak KJ. Analyzing real-Time PCR data by the comparative C(T) method. Nat Protocols 2008; 3: 1101-1108. (Pubitemid 351818697)